Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00283543
Verified October 2007 by Kentuckiana Cancer Institute. Recruitment status was: Active, not recruiting
To determine the safety and efficacy of Gliadel 3.85% wafers plus surgery and radiation with Temozolomide
Condition or disease
Newly Diagnosed Supratentorial Malignant Glioma
Drug: Gliadel WaferDrug: TemozolomideProcedure: Limited field radiation
A phase II study of radiation with concomitant and then sequential Temozolomide in patients with newly diagnosed supratentorial malignant glioma who have undergone surgery with Gliadel wafer insertion. To determine the safety and efficacy of Gliadel 3.85% wafers plus surgery and limited field radiation therapy with concomitant Temozolomide followed by Temozolomide alone in patients undergoing initial surgery for newly diagnosed unifocal moderate to high grade glioma.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.